A new post-marketing clinical trial is underway for Vliwazell®, a wound dressing developed by Lohmann & Rauscher, designed for both acute and chronic wounds. This critical initiative, focusing on the product’s real-world performance, could lead to improved confidence in its clinical and regulatory validity for healthcare providers and patients with complex wound care needs.
What changed?
The clinical trial, officially sponsored by Lohmann & Rauscher, is currently in its recruiting phase. It focuses on the post-marketing surveillance of Vliwazell®, a wound dressing used for managing acute and chronic wounds. This is a regulatory milestone for the medical device, emphasizing responsible post-market monitoring to evaluate product performance and patient outcomes.
Why this matters?
Post-marketing surveillance is an essential part of medical device regulations, ensuring safety and effectiveness after market entry. Acute and chronic wounds represent a significant global healthcare challenge. Confirming the reliability of Vliwazell® through clinical data can guide clinicians in choosing suitable treatment options while ensuring compliance with regulatory standards.
More about the trial
The trial will study Vliwazell®’s real-world application and its effectiveness in diverse patient populations diagnosed with acute or chronic wounds. Recruitment is actively underway, targeting participants who meet pre-defined eligibility criteria. This phase allows stakeholders to collect comprehensive data on safety and clinical outcomes, contributing to continuous improvement in device performance.
Manufactured by Lohmann & Rauscher, Vliwazell® is intended to provide safe and effective wound healing support. Regulatory authorities worldwide emphasize the importance of post-market studies to monitor medical devices under customary use conditions. This study aligns with those directives.
FAQ
- What is Vliwazell®?
Vliwazell® is a wound dressing designed for managing acute and chronic wounds. - What is the focus of the study?
The study is a post-marketing surveillance to evaluate Vliwazell®’s efficacy and safety under real-world conditions. - Who is the sponsor of the trial?
The sponsor is Lohmann & Rauscher. - Is the trial actively recruiting patients?
Yes, recruitment is currently open. - How will this trial help?
The data collected will support clinical decision-making, safety assurance, and regulatory compliance.
Conclusion
The ongoing post-marketing surveillance of Vliwazell® reinforces Lohmann & Rauscher’s commitment to patient safety and regulatory adherence. For professionals involved in wound care, this study provides an opportunity to monitor advancements in treatment strategies for acute and chronic wounds. Clinical and regulatory teams should stay informed about the study results.
Disclaimer
This article is for informational purposes only and is not intended as legal or regulatory advice. Consult a regulatory expert for guidance specific to your situation.
Full announcement link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07316556?term=medical+device